Loading stock data…
Seer (SEER)
$1.95
Market ClosedLast close Sep 8
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Seer, Inc. in the Healthcare sector is trading at $1.95 with a market capitalization of $95M. Wall Street consensus targets $4.00 (1 analysts), implying a +105.1% move over the next 12 months. The stock is currently 19% below its 52-week high of $2.41, remaining 3.2% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +105.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.71M↓ | $4.07M↑ | $3.97M↑ | $3.93M↓ | $4.14M |
| Gross Profit | $895,000↓ | $2.06M↑ | $1.96M↓ | $1.99M↓ | $2.00M |
| Operating Income | -$17.26M↑ | -$17.39M↑ | -$19.35M↑ | -$20.53M↑ | -$20.73M |
| Net Income | -$16.84M↓ | -$15.99M↑ | -$18.23M↑ | -$19.42M↑ | -$19.95M |
Peer Comparison
JNJUNHPFE
Fundamentals
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Pr...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$95.12M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-29.19%
Volume
Today's trading volume
193,737
Recent News
Seer (SEER) Q2 2026 Earnings Call Transcript
Revenue grew to $3.1 million despite academic funding headwinds.
Seer, Inc. Q2 2026 Earnings Call Summary
Moby summary of Seer, Inc.'s Q2 2026 earnings call
Seer Inc (SEER) (Q2 2026) Earnings Call Highlights: Navigating Funding Headwinds While ...
Seer Inc (SEER) reaffirms full-year guidance despite a year-over-year revenue dip, bolstered by strong cash reserves, groundbreaking independent validations, and promising AI cancer screening data.
Seer Q2 Earnings Call Highlights
Seer (NASDAQ:SEER) reported second-quarter revenue of $3.1 million, down from $4.1 million a year earlier but up from $2.8 million in the first quarter, as the proteomics company cited continued pressure on academic and government funding and longer sales cycles among some commercial customers. Chi
Sector Update: Healthcare Stocks Gain Late Afternoon
Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index rising 2.3% and